Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6562574 | 0.81 | EPHX1 (0.39) | MEN1KMT2ALMNAKCNH2CA2 | |
| SCHEMBL6562558 | 0.81 | LMNA (0.38) | MEN1KMT2ALMNAKCNH2NPC1 | |
| SCHEMBL6563610 | 0.81 | LMNA (0.36) | MEN1KMT2ALMNAKCNH2NPC1 | |
| SCHEMBL6563464 | 0.81 | MEN1 (0.39) | MEN1KMT2ALMNAKCNH2NPC1 | |
| SCHEMBL438991 | 0.79 | MEN1 (0.43) | MEN1KMT2ALMNAKCNH2NPC1 | |
| SCHEMBL438992 | 0.79 | MEN1 (0.43) | MEN1KMT2ALMNAKCNH2NPC1 | |
| SCHEMBL1493211 | 0.76 | NPC1 (0.38) | NPC1RAB9ACA2 | |
| SCHEMBL6560897 | 0.75 | KCNH2 (0.39) | MEN1KMT2ALMNAKCNH2NPC1 | |
| SCHEMBL13814023 | 0.72 | KCNH2 (0.45) | MEN1KMT2ALMNAKCNH2NPC1 | |
| SCHEMBL13814024 | 0.72 | KCNH2 (0.45) | MEN1KMT2ALMNAKCNH2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040258620-A1 | (Ethylene)-( propylene)-triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2004-12-23 | — | — | US | disclosed |
| US-20030194371-A1 | (Ethylene)-(propylene) - triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040258620-A1 | (Ethylene)-( propylene)-triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | EEA1, PCTP, TTPA | MEN1 1437/4885KMT2A 1141/4885LMNA 3545/4885 |
| US-20030194371-A1 | (Ethylene)-(propylene) - triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | PGD, AADAT, TRHDE | MEN1 439/4885KMT2A 3824/4885LMNA 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.